CHICAGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported updated data from a pivotal trial of brentuximab vedotin (ADCETRIS™) in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of Hodgkin lymphoma and systemic ALCL, and a target also expressed in other malignancies. The updated data were presented today during poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting being held in Chicago, IL.
